Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer.

Koopman LA, Terp MG, Zom GG, Janmaat ML, Jacobsen K, Gresnigt-Van den Heuvel E, Brandhorst M, Forssmann U, de Bree FM, Pencheva N, Lingnau A, Zipeto MA, Parren PW, Breij EC, Ditzel HJ.

JCI Insight. 2019 Oct 10. pii: 128199. doi: 10.1172/jci.insight.128199. [Epub ahead of print]

2.

ARAP1 is an independent prognostic biomarker in older women with ovarian high-grade serous adenocarcinoma receiving first-line platinum-based antineoplastic therapy.

Nadaraja S, Schledermann D, Herrstedt J, Østrup O, Ditzel HJ; Academy of Geriatric Cancer Research (AgeCare).

Acta Oncol. 2019 Sep 3:1-8. doi: 10.1080/0284186X.2019.1657941. [Epub ahead of print]

PMID:
31478407
3.

Chimeric antigen receptor T cells targeting CD79b show efficacy in lymphoma with or without co-targeting CD19.

Ormhøj M, Scarfò I, Cabral ML, Bailey SR, Lorrey SJ, Bouffard AA, Castano AP, Larson RC, Riley LS, Schmidts A, Choi BD, Andersen RS, Cédile O, Nyvold CG, Haaber J, Gjerstorff MF, Ditzel HJ, Weinstock DM, Barington T, Frigault MJ, Maus MV.

Clin Cancer Res. 2019 Aug 22. pii: clincanres.1337.2019. doi: 10.1158/1078-0432.CCR-19-1337. [Epub ahead of print]

PMID:
31439577
4.

Increased Cholesterol Biosynthesis Is a Key Characteristic of Breast Cancer Stem Cells Influencing Patient Outcome.

Ehmsen S, Pedersen MH, Wang G, Terp MG, Arslanagic A, Hood BL, Conrads TP, Leth-Larsen R, Ditzel HJ.

Cell Rep. 2019 Jun 25;27(13):3927-3938.e6. doi: 10.1016/j.celrep.2019.05.104.

5.

Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC.

Røsland GV, Dyrstad SE, Tusubira D, Helwa R, Tan TZ, Lotsberg ML, Pettersen IKN, Berg A, Kindt C, Hoel F, Jacobsen K, Arason AJ, Engelsen AST, Ditzel HJ, Lønning PE, Krakstad C, Thiery JP, Lorens JB, Knappskog S, Tronstad KJ.

Cancer Metab. 2019 Jun 1;7:6. doi: 10.1186/s40170-019-0197-8. eCollection 2019.

6.

Remodeling and destabilization of chromosome 1 pericentromeric heterochromatin by SSX proteins.

Traynor S, Møllegaard NE, Jørgensen MG, Brückmann NH, Pedersen CB, Terp MG, Johansen S, Dejardin J, Ditzel HJ, Gjerstorff MF.

Nucleic Acids Res. 2019 Jul 26;47(13):6668-6684. doi: 10.1093/nar/gkz396.

7.

Human DREF/ZBED1 is a nuclear protein widely expressed in multiple cell types derived from all three primary germ layers.

Hansen SV, Traynor S, Ditzel HJ, Gjerstorff MF.

PLoS One. 2018 Oct 10;13(10):e0205461. doi: 10.1371/journal.pone.0205461. eCollection 2018.

8.

KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancer.

Wang W, Oguz G, Lee PL, Bao Y, Wang P, Terp MG, Ditzel HJ, Yu Q.

J Exp Med. 2018 Nov 5;215(11):2833-2849. doi: 10.1084/jem.20180439. Epub 2018 Sep 28.

9.

Correction: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy.

Elias D, Vever H, Lænkholm AV, Gjerstorff MF, Yde CW, Lykkesfeldt AE, Ditzel HJ.

Oncogene. 2018 Oct;37(41):5585-5586. doi: 10.1038/s41388-018-0495-6.

PMID:
30242243
10.

Human cancer evolution in the context of a human immune system in mice.

Gammelgaard OL, Terp MG, Preiss B, Ditzel HJ.

Mol Oncol. 2018 Oct;12(10):1797-1810. doi: 10.1002/1878-0261.12374. Epub 2018 Sep 3.

11.

CYPOR is a novel and independent prognostic biomarker of recurrence-free survival in triple-negative breast cancer patients.

Pedersen MH, Hood BL, Ehmsen S, Beck HC, Conrads TP, Bak M, Ditzel HJ, Leth-Larsen R.

Int J Cancer. 2019 Feb 1;144(3):631-640. doi: 10.1002/ijc.31798. Epub 2018 Nov 7.

PMID:
30110125
13.

Selective elimination of senescent cells by mitochondrial targeting is regulated by ANT2.

Hubackova S, Davidova E, Rohlenova K, Stursa J, Werner L, Andera L, Dong L, Terp MG, Hodny Z, Ditzel HJ, Rohlena J, Neuzil J.

Cell Death Differ. 2019 Jan;26(2):276-290. doi: 10.1038/s41418-018-0118-3. Epub 2018 May 21.

14.

Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer.

Kodahl AR, Ehmsen S, Pallisgaard N, Jylling AMB, Jensen JD, Laenkholm AV, Knoop AS, Ditzel HJ.

Mol Oncol. 2018 Jun;12(6):925-935. doi: 10.1002/1878-0261.12305. Epub 2018 May 4.

15.

Coexisting genomic aberrations associated with lymph node metastasis in breast cancer.

Bao L, Qian Z, Lyng MB, Wang L, Yu Y, Wang T, Zhang X, Yang H, Brünner N, Wang J, Ditzel HJ.

J Clin Invest. 2018 Jun 1;128(6):2310-2324. doi: 10.1172/JCI97449. Epub 2018 Apr 23.

16.

Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells.

Kirkin AF, Dzhandzhugazyan KN, Guldberg P, Fang JJ, Andersen RS, Dahl C, Mortensen J, Lundby T, Wagner A, Law I, Broholm H, Madsen L, Lundell-Ek C, Gjerstorff MF, Ditzel HJ, Jensen MR, Fischer W.

Nat Commun. 2018 Mar 6;9(1):785. doi: 10.1038/s41467-018-03217-9.

17.

Epigenetic Reprogramming of Pericentromeric Satellite DNA in Premalignant and Malignant Lesions.

Brückmann NH, Pedersen CB, Ditzel HJ, Gjerstorff MF.

Mol Cancer Res. 2018 Mar;16(3):417-427. doi: 10.1158/1541-7786.MCR-17-0477. Epub 2018 Jan 12.

18.

One-step FPLC-size-exclusion chromatography procedure for purification of rDMBT1 6 kb with increased biological activity.

Tuttolomondo M, Hansen PL, Mollenhauer J, Ditzel HJ.

Anal Biochem. 2018 Feb 1;542:16-19. doi: 10.1016/j.ab.2017.11.015. Epub 2017 Nov 21.

PMID:
29169777
19.

Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence.

Goh JY, Feng M, Wang W, Oguz G, Yatim SMJM, Lee PL, Bao Y, Lim TH, Wang P, Tam WL, Kodahl AR, Lyng MB, Sarma S, Lin SY, Lezhava A, Yap YS, Lim AST, Hoon DSB, Ditzel HJ, Lee SC, Tan EY, Yu Q.

Nat Med. 2017 Nov;23(11):1319-1330. doi: 10.1038/nm.4405. Epub 2017 Sep 25.

PMID:
28967919
20.

De novo pathway-based biomarker identification.

Alcaraz N, List M, Batra R, Vandin F, Ditzel HJ, Baumbach J.

Nucleic Acids Res. 2017 Sep 19;45(16):e151. doi: 10.1093/nar/gkx642.

21.

Human DMBT1-Derived Cell-Penetrating Peptides for Intracellular siRNA Delivery.

Tuttolomondo M, Casella C, Hansen PL, Polo E, Herda LM, Dawson KA, Ditzel HJ, Mollenhauer J.

Mol Ther Nucleic Acids. 2017 Sep 15;8:264-276. doi: 10.1016/j.omtn.2017.06.020. Epub 2017 Jun 29.

22.

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer.

Jacobsen K, Bertran-Alamillo J, Molina MA, Teixidó C, Karachaliou N, Pedersen MH, Castellví J, Garzón M, Codony-Servat C, Codony-Servat J, Giménez-Capitán A, Drozdowskyj A, Viteri S, Larsen MR, Lassen U, Felip E, Bivona TG, Ditzel HJ, Rosell R.

Nat Commun. 2017 Sep 4;8(1):410. doi: 10.1038/s41467-017-00450-6.

23.

On the performance of de novo pathway enrichment.

Batra R, Alcaraz N, Gitzhofer K, Pauling J, Ditzel HJ, Hellmuth M, Baumbach J, List M.

NPJ Syst Biol Appl. 2017 Mar 3;3:6. doi: 10.1038/s41540-017-0007-2. eCollection 2017.

24.

Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors.

Pedersen MH, Hood BL, Beck HC, Conrads TP, Ditzel HJ, Leth-Larsen R.

Oncoimmunology. 2017 Mar 16;6(5):e1305531. doi: 10.1080/2162402X.2017.1305531. eCollection 2017.

25.

Elucidation of Altered Pathways in Tumor-Initiating Cells of Triple-Negative Breast Cancer: A Useful Cell Model System for Drug Screening.

Christensen AG, Ehmsen S, Terp MG, Batra R, Alcaraz N, Baumbach J, Noer JB, Moreira J, Leth-Larsen R, Larsen MR, Ditzel HJ.

Stem Cells. 2017 Aug;35(8):1898-1912. doi: 10.1002/stem.2654. Epub 2017 Jun 23.

26.

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.

Chaib I, Karachaliou N, Pilotto S, Codony Servat J, Cai X, Li X, Drozdowskyj A, Servat CC, Yang J, Hu C, Cardona AF, Vivanco GL, Vergnenegre A, Sanchez JM, Provencio M, de Marinis F, Passaro A, Carcereny E, Reguart N, Campelo CG, Teixido C, Sperduti I, Rodriguez S, Lazzari C, Verlicchi A, de Aguirre I, Queralt C, Wei J, Estrada R, Puig de la Bellacasa R, Ramirez JL, Jacobson K, Ditzel HJ, Santarpia M, Viteri S, Molina MA, Zhou C, Cao P, Ma PC, Bivona TG, Rosell R.

J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx014.

27.

Prospective validation of a blood-based 9-miRNA profile for early detection of breast cancer in a cohort of women examined by clinical mammography.

Lyng MB, Kodahl AR, Binder H, Ditzel HJ.

Mol Oncol. 2016 Dec;10(10):1621-1626. doi: 10.1016/j.molonc.2016.10.004. Epub 2016 Nov 1.

28.

Tumor-selective replication herpes simplex virus-based technology significantly improves clinical detection and prognostication of viable circulating tumor cells.

Zhang W, Bao L, Yang S, Qian Z, Dong M, Yin L, Zhao Q, Ge K, Deng Z, Zhang J, Qi F, An Z, Yu Y, Wang Q, Wu R, Fan F, Zhang L, Chen X, Na Y, Feng L, Liu L, Zhu Y, Qin T, Zhang S, Zhang Y, Zhang X, Wang J, Yi X, Zou L, Xin HW, Ditzel HJ, Gao H, Zhang K, Liu B, Cheng S.

Oncotarget. 2016 Jun 28;7(26):39768-39783. doi: 10.18632/oncotarget.9465.

29.

Robust de novo pathway enrichment with KeyPathwayMiner 5.

Alcaraz N, List M, Dissing-Hansen M, Rehmsmeier M, Tan Q, Mollenhauer J, Ditzel HJ, Baumbach J.

F1000Res. 2016 Jun 28;5:1531. doi: 10.12688/f1000research.9054.1. eCollection 2016.

30.

Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer.

Joshi T, Elias D, Stenvang J, Alves CL, Teng F, Lyng MB, Lykkesfeldt AE, Brünner N, Wang J, Gupta R, Workman CT, Ditzel HJ.

Oncotarget. 2016 Aug 30;7(35):57239-57253. doi: 10.18632/oncotarget.11136.

31.

The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells.

Hansen SN, Ehlers NS, Zhu S, Thomsen MB, Nielsen RL, Liu D, Wang G, Hou Y, Zhang X, Xu X, Bolund L, Yang H, Wang J, Moreira J, Ditzel HJ, Brünner N, Schrohl AS, Stenvang J, Gupta R.

BMC Genomics. 2016 Jun 9;17:442. doi: 10.1186/s12864-016-2749-4.

32.

High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.

Alves CL, Elias D, Lyng M, Bak M, Kirkegaard T, Lykkesfeldt AE, Ditzel HJ.

Clin Cancer Res. 2016 Nov 15;22(22):5514-5526. doi: 10.1158/1078-0432.CCR-15-1984. Epub 2016 Jun 1.

33.

KeyPathwayMinerWeb: online multi-omics network enrichment.

List M, Alcaraz N, Dissing-Hansen M, Ditzel HJ, Mollenhauer J, Baumbach J.

Nucleic Acids Res. 2016 Jul 8;44(W1):W98-W104. doi: 10.1093/nar/gkw373. Epub 2016 May 5.

34.

Development of a specific affinity-matured exosite inhibitor to MT1-MMP that efficiently inhibits tumor cell invasion in vitro and metastasis in vivo.

Botkjaer KA, Kwok HF, Terp MG, Karatt-Vellatt A, Santamaria S, McCafferty J, Andreasen PA, Itoh Y, Ditzel HJ, Murphy G.

Oncotarget. 2016 Mar 29;7(13):16773-92. doi: 10.18632/oncotarget.7780.

35.

HIF2α contributes to antiestrogen resistance via positive bilateral crosstalk with EGFR in breast cancer cells.

Alam MW, Persson CU, Reinbothe S, Kazi JU, Rönnstrand L, Wigerup C, Ditzel HJ, Lykkesfeldt AE, Påhlman S, Jögi A.

Oncotarget. 2016 Mar 8;7(10):11238-50. doi: 10.18632/oncotarget.7167.

36.

The role of GAGE cancer/testis antigen in metastasis: the jury is still out.

Gjerstorff MF, Terp MG, Hansen MB, Ditzel HJ.

BMC Cancer. 2016 Jan 8;16:7. doi: 10.1186/s12885-015-1998-y.

37.

The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.

Ignatiadis M, Azim HA Jr, Desmedt C, Veys I, Larsimont D, Salgado R, Lyng MB, Viale G, Leyland-Jones B, Giobbie-Hurder A, Kammler R, Dell'Orto P, Rothé F, Laïos I, Ditzel HJ, Regan MM, Piccart M, Michiels S, Sotiriou C.

JAMA Oncol. 2016 Feb;2(2):217-24. doi: 10.1001/jamaoncol.2015.4377.

PMID:
26633571
38.

Corrigendum: IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.

Wee ZN, Yatim SMJM, Kohlabauer VK, Feng M, Goh JY, Bao Y, Lee PL, Zhang S, Wang PP, Lim E, Tam WL, Cai Y, Ditzel HJ, Hoon DSB, Tan EY, Yu Q.

Nat Commun. 2015 Nov 20;6:10054. doi: 10.1038/ncomms10054. No abstract available.

PMID:
26585835
39.

Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.

Thomsen KG, Lyng MB, Elias D, Vever H, Knoop AS, Lykkesfeldt AE, Lænkholm AV, Ditzel HJ.

Breast Cancer Res Treat. 2015 Dec;154(3):483-94. doi: 10.1007/s10549-015-3644-4. Epub 2015 Nov 19.

PMID:
26585578
40.

IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.

Wee ZN, Yatim SM, Kohlbauer VK, Feng M, Goh JY, Bao Y, Lee PL, Zhang S, Wang PP, Lim E, Tam WL, Cai Y, Ditzel HJ, Hoon DS, Tan EY, Yu Q.

Nat Commun. 2015 Oct 27;6:8746. doi: 10.1038/ncomms9746. Erratum in: Nat Commun. 2015;6:10054. Yi, Bao [Corrected to Bao, Yi].

41.

The potential of Src inhibitors.

Elias D, Ditzel HJ.

Aging (Albany NY). 2015 Oct;7(10):734-5. No abstract available.

42.

NADH-Cytochrome b5 Reductase 3 Promotes Colonization and Metastasis Formation and Is a Prognostic Marker of Disease-Free and Overall Survival in Estrogen Receptor-Negative Breast Cancer.

Lund RR, Leth-Larsen R, Caterino TD, Terp MG, Nissen J, Lænkholm AV, Jensen ON, Ditzel HJ.

Mol Cell Proteomics. 2015 Nov;14(11):2988-99. doi: 10.1074/mcp.M115.050385. Epub 2015 Sep 8.

43.

miR-155, identified as anti-metastatic by global miRNA profiling of a metastasis model, inhibits cancer cell extravasation and colonization in vivo and causes significant signaling alterations.

Thomsen KG, Terp MG, Lund RR, Søkilde R, Elias D, Bak M, Litman T, Beck HC, Lyng MB, Ditzel HJ.

Oncotarget. 2015 Oct 6;6(30):29224-39. doi: 10.18632/oncotarget.4942.

44.

Fyn is an important molecule in cancer pathogenesis and drug resistance.

Elias D, Ditzel HJ.

Pharmacol Res. 2015 Oct;100:250-4. doi: 10.1016/j.phrs.2015.08.010. Epub 2015 Aug 21. Review.

PMID:
26305432
45.

Lack of ADAM2, CALR3 and SAGE1 Cancer/Testis Antigen Expression in Lung and Breast Cancer.

Maheswaran E, Pedersen CB, Ditzel HJ, Gjerstorff MF.

PLoS One. 2015 Aug 7;10(8):e0134967. doi: 10.1371/journal.pone.0134967. eCollection 2015.

46.

Detecting Plasma Tumor DNA in Early-Stage Breast Cancer-Letter.

Kodahl AR, Pallisgaard N, Jylling AM, Cold S, Knoop AS, Ditzel HJ.

Clin Cancer Res. 2015 Aug 1;21(15):3569. doi: 10.1158/1078-0432.CCR-15-0776. No abstract available.

47.

Oncogenic cancer/testis antigens: prime candidates for immunotherapy.

Gjerstorff MF, Andersen MH, Ditzel HJ.

Oncotarget. 2015 Jun 30;6(18):15772-87. Review.

48.

Keratin 34betaE12/keratin7 expression is a prognostic factor of cancer-specific and overall survival in patients with early stage non-small cell lung cancer.

Pøhl M, Olsen KE, Holst R, Donnem T, Busund LT, Bremnes RM, Al-Saad S, Andersen S, Richardsen E, Ditzel HJ, Hansen O.

Acta Oncol. 2016;55(2):167-77. doi: 10.3109/0284186X.2015.1049291. Epub 2015 Jun 9.

PMID:
26057535
49.

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.

Leyland-Jones B, Gray KP, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Harvey VJ, Neven P, Treilleux I, Rasmussen BB, Maibach R, Price KN, Coates AS, Goldhirsch A, Pagani O, Viale G, Rae JM, Regan MM.

Breast Cancer Res Treat. 2015 Jun;151(2):373-84. doi: 10.1007/s10549-015-3378-3. Epub 2015 May 3.

50.

S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype.

Ehmsen S, Hansen LT, Bak M, Brasch-Andersen C, Ditzel HJ, Leth-Larsen R.

Int J Cancer. 2015 Nov 1;137(9):2093-103. doi: 10.1002/ijc.29582. Epub 2015 May 21.

Supplemental Content

Loading ...
Support Center